CKPT Rentabilitas operasi Checkpoint Therapeutics Inc.

checkpointtx.com (CKPT) - logo korporat

The market for targeted antibodies for the therapy of squamous cell skin cancer is currently growing rapidly due to the availability of new solutions. EBIT profitability demonstrates current efficiency, with the parameter value reaching -137500.00. Checkpoint Therapeutics (CKPT) positions are strengthened by patents for Cosibelimab, which guarantee high margins, while a strategic alliance with TG Therapeutics allows for the consolidation of scientific potential to create advanced oncology drugs.

checkpointtx.com (CKPT): Rentabilitas dodolan operasi saka 04.07.2022 nganti 07.06.2025

Rincian analitis perusahaan Checkpoint Therapeutics, Inc. (CKPT)

Pambiji fundamental:Checkpoint Therapeutics, Inc
Barang utama checkpointtx.com

To identify stability drivers, the investor analyzes the operating profit-to-revenue ratio, which allows for an assessment of business process efficiency before accounting for debt load and taxes. The average operating margin, which reached -137500.00, reflects the cost of maintaining the R&D core and hiring top management necessary for Checkpoint Therapeutics (CKPT) to successfully advance drugs through clinical trial phases.

Analisis pesaing Checkpoint Therapeutics

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Rentabilitas dodolan operasi|RADX - Rentabilitas operasi|ARTV - Margin operasi|Adlai Nortye Ltd (ANL) - Rentabilitas operasi|Veru Pharma - Tingkat bathi operasi|Rentabilitas operasi Tempest Therapeutics Corp|Rentabilitas dodolan miturut bathi operasi XLO (Xilio Therapeutics, Inc.)|Margin operasi RENB|MURA (Mural Oncology) - Tingkat bathi operasi|Margin operasi KAPA (Kairos Pharma Ltd)|OKUR: Rentabilitas dodolan miturut bathi operasi|GDTC: Margin dodolan operasi|CRIS - Margin operasi|APLM: Margin operasi|Rentabilitas dodolan operasi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Margin operasi|Margin operasi Genprex Inc.|Margin operasi CLDI|Margin dodolan operasi Sunshine Biopharma, Inc. SBFM|Margin operasi XBIO (Xenetic Biosciences)|Tingkat bathi operasi SLRX|PPBT - Rentabilitas operasi|AONC (aoncology.com) - Rentabilitas dodolan miturut bathi operasi|BGNE: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi